Anadys Pharmaceuticals, Inc.

Other

Scriptgen Pharmaceuticals, Inc.

Xtl Biopharmaceuticals Ltd.

C Richard Wobbe

John D Bradley

Judith M Healy

Craig M Thompson

Jeffrey B Moore

Reza Fathi

Zhen Yang

Qiang Zhu

Yixin Liu

Anthony Sandrasagra

Hyun-Joon Cho

Jason A Thresher

Caroline E Donnelly

Stephen Buratowski

Robert H Murray

Nicholas J Sisti

Zhe Li

Yi Bin Xiang

Yun Liao

Yueh-Tyng Chien

Kenneth Nawoschik

Vincent Boyd

David A Bailey

Patricia Carroll

Guolin Li

Andrei Caracoti

Angela Lam

Daniel Moore

Jie Cao

Pamela Mingo

Shuhao Zhu

Wu Ruoqiu

Peng Wang

Xiaodan Mei

The present invention relates to 4-thio substituted quinoline and naphthyridine derivatives and processes for their preparation. The invention also related to methods for treating infection of Hepatitis C virus by administering a 4-thio substituted quinoline or naphthyridine derivative.

4-thio substituted quinoline and naphthyridine compounds

Aryl substituted pyrazole derivatives are provided, as well as processes for their preparation. The invention also provides compositions and methods for the treatment of HCV by administering a compound of the present invention, alone or in combination with additional antiviral agents, in a therapeutically effective amount.

4-ethynyl pyrazole derivative compounds and methods for treatment of HCV

The present invention provides an isolated Staphylococcal GTPase obg gene and a Staphylococcal GTP-binding protein encoded thereby. A recombinant expression vector and an engineered host cell are also provided that include a polynucleotide encoding a Staphylococcal GTP-binding protein. The present invention further relates to a method of producing Staphylococcal GTP-binding protein and a method for high throughput screening to identify potential antimicrobial compounds useful against Staphylococcal bacterial strains.

Staphylococcal GTPase obg nucleotide sequence encoding Staphylococcal GTP-binding protein

The invention provides novel yeast cells comprising genes whose expression can be modulated by growth in the presence or absence of metal ions, methods for making such yeast cells, and methods of using such yeast cells for determining the requirement for expression of particular genes for the growth or viability of the yeast cells. The invention also provides methods of using such yeast cells in the isolation, screening and analysis of candidate antifungal compounds.

Regulated gene expression in yeast and method of use

The present invention relates to a recombinant organism, and a bacterial strain such as Staphylococcus, and , in particular. The organism has a regulatable gene for encoding an RNA polymerase specificity factor required for expression of at least one gene essential for growth of the organism. The regulatable gene is one which is responsive to an exogenous effector molecule, and may in particular be an inducer-responsive gene including an operator site, such as a lac operator, to which a repressor, such as a lacl-encoded repressor, is capable of binding. The regulatable gene may in particular be an IPTG responsive plaC allele.

Staphylococcus strains comprising an inducible gene encoding an RNA polymerase specificity factor

The invention provides novel yeast cells comprising genes whose expression can be modulated by growth in the presence or absence of metal ions, methods for making such yeast cells, and methods of using such yeast cells for determining the requirement for expression of particular genes for the growth or viability of the yeast cells.

Regulated gene expression in yeast

Disclosed are pharmaceutical compositions comprising aryl and heteroaryl hydrazone, hydrazine and thiosemicarbazone derivatives of formulae I and II, and methods for using the compositions as antifungal agents. The invention also relates to novel aryl and heteroaryl hydrazone, hydrazine and thiosemicarbazone derivatives of formulae I and II, their preparation, to pharmaceutical compositions containing them, and to methods of using them to alleviate fungal infections.

Hydrazone, hydrazine and thiosemicarbazone derivatives as antifungal agents

The invention encompasses a novel transcription factor from,, TFIIB, a nucleic acid sequence encoding TFIIB, and methods of screening for inhibitors of,growth by targeting TFIIB.

TFIIB transcription factor from Candida albicans and methods of screening for inhibitors of Candida albicans growth

The present invention provides azo and stilbene compounds having the structure: wherein XY is N.dbd.N, CH.dbd.CH, (C.dbd.O)--NH or NH--(C.dbd.O); wherein Z is CR.sub.6 or N; wherein R.sub.1, R.sub.2 and R.sub.5 are independently hydrogen, halogen, NO.sub.2 or CF.sub.3 ; wherein R.sub.3 is hydrogen, halogen, CF.sub.3, aryl or heteroaryl, NO.sub.2 or OCF.sub.3 ; wherein R.sub.4 is hydrogen, halogen, CF.sub.3, aryl or heteroaryl, NO.sub.2 or linear or branched chain alkoxy; wherein R.sub.6 is hydrogen or linear or branched alkyl; wherein R.sub.7 is hydrogen, cyano, hydroxyalkyl, carboxyl, halogen, hydroxyl, formyl, NO.sub.2 or halogen; and wherein R.sub.8 is hydroxyl or substituted or unsubstituted amino; and wherein R.sub.9 and R.sub.10 are independently hydrogen, CN or hydroxyalkyl. Said compounds are useful as antifungal therapeutics, fungicides and fungistats. The present invention also provides methods of inhibiting fungal RNA transcription and treating fungal infections in human and animal subjects and fungal infestations in plants.

Antifungal agents

The invention encompasses a novel transcription factor from Candida albicans, TFIIB, a nucleic acid sequence encoding TFIIB, and methods of screening for inhibitors of Candida albicans growth by targeting TFIIB.

Nucleic acids encoding TFIIB transcription factor from candida albicans

Growing community of inventors

Lexington, MA, United States of America

C Richard Wobbe